NCT00272792
Phenylketonuria, Phenylketonurias
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The primary objective of this trial is to evaluate the ability of Phenoptin to increase phenylalanine (phe) tolerance in children with phenylketonuria who are following a phe-restricted diet.
All
4 Years to 12 Years
No
Sapropterin Dihydrochloride, Placebo
Phase 3
Interventional
45
2006-02
2015-08-13
Los Angeles, California, United States
Oakland, California, United States
Sacramento, California, United States
San Jose, California, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Minneapolis, Minnesota, United States
St. Louis, Missouri, United States
Salt Lake City, Utah, United States
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields